The next few years will see substantial growth across different geographies and therapeutic areas. This will enable the Mundipharma independent associated companies to further the development of new, innovative treatments that will greatly enhance the lives of patients.

Arvind Agrawal, Head of Medical Affairs
 

Products

Over the past 50 years, the network of Mundipharma independent associated companies has established their expertise in analgesics and expanded their research and development capabilities into a number of other therapeutic areas.

The current product range detailed below varies from country to country depending on market authorisations.


Trade name Generic name Therapy area Countries availability
flutiform▼®
flutiformo®
fluticasone propionate / formoterol Asthma Australia, Belgium, Cyprus, Czech Republic, France, Denmark, Finland, Germany, Hong-Kong, Iceland, Ireland, Italy, Netherlands, Norway, Slovakia, South Korea, Sweden, UK

fluticasone proprionate/formoterol is also approved for use in other countries where Mundipharma does not control rights to the product
Levact▼®
Ribomustin®
Ribovact®
bendamustine hydrochloride  Haematological malignancies Approved for use in the following Mundipharma territories: Austria, Belgium, Bulgaria, Denmark, Cyprus, Czech Republic, Finland, France, Germany, Iceland, Ireland, Italy, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland and the UK

Bendamustine hydrochloride is also approved for use in other countries where Mundipharma does not control rights to the product
DepoCyte® cytarabine Haematological malignancies Approved for use in the following Mundipharma territories: South Korea, Switzerland and throughout the European Union

Cytarabine is also approved for use in other countries where Mundipharma does not control rights to the product
Folotyn® pralatrexate Haematological malignancies Approved for use in the following Mundipharma territories: Israel and South Korea

Folotyn® is undergoing regulatory assessment in a number of Mundipharma territories including Asia, Australasia, Latin America and other Middle Eastern countries

Pralatrexate is also approved for use in other countries where Mundipharma does not control rights to the product
BuTrans®
Norspan®
buprenorphine Pain Denmark, Finland, Germany, Ireland, Netherlands, Norway, Sweden, UK
Palladon®
Palladone®
Hydal®
hydromorphone (immediate release) Pain Austria, Belgium, Denmark, Finland, Germany, Ireland, Luxembourg, Netherlands, Norway, Sweden, Switzerland, UK
Palladon®
Palladone®
Hydal®
hydromorphone injection Pain Austria, Belgium, Denmark, Germany, Luxembourg, Sweden, Switzerland
Palladon®
Palladone®
Hydal®
Sophidone®
hydromorphone (prolonged release) Pain Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Iceland, Ireland, Luxembourg, Netherlands, Norway, Spain, Slovakia, Slovenia, Sweden, Switzerland, UK
OxyNorm® oxycodone (immediate release) Pain Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Luxembourg, Netherlands, Norway, Poland, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK
OxyContin® OxyGesic® oxycodone (prolonged release) Pain Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, France, Denmark, Finland, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Luxembourg, Netherlands, Norway, Poland, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK
Targin®
Targinact▼®
Targiniq®
oxycodone
naloxone
Pain European Union & Switzerland
Lodotra® modified-release prednisone Rheumatoid arthritis Austria, Belgium, Denmark, Finland, Germany, Israel, Italy, Luxembourg, Netherlands, Norway, Poland, Sweden, Switzerland, UK

Please refer to individual countries for full product indication, and local prescribing information.

Our associate network is actively involved in four therapeutic areas: